Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemia: Integrating genomics into therapyCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationPrognostic factors and treatment of pediatric acute lymphoblastic leukemia.Biology of childhood acute lymphoblastic leukemia.Remaining challenges in childhood cancer and newer targeted therapeutics.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Novel agents for the treatment of childhood acute leukemia.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04Improving access to novel agents for childhood leukemia.A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Favorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.Improving the outcome for children with cancer: Development of targeted new agents.Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.Pediatric chronic myeloid leukemia is a unique disease that requires a different approachCharacterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Novel approaches to pediatric leukemia treatment.Adolescent and young adult patients with cancer: a milieu of unique features.Therapies on the horizon for childhood acute lymphoblastic leukemia.Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.Ph-like acute lymphoblastic leukemia.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Treatment of Young Adults with Acute Lymphoblastic Leukemia.
P2860
Q26768158-A7A9E692-06C7-4562-BBC9-44147D9FB5AFQ26781328-1F8E8203-2487-4322-845A-DD2EB0A6E678Q27025242-FCFAF762-13A7-4103-9098-07309760763AQ28080463-E8F6FC78-A176-44DA-9043-30C5E6C3CA69Q28084879-EA336049-7DE2-472C-AF35-6A48C3018EBAQ28087637-4B7F0F88-7285-4F67-8214-961C7257353BQ33770150-C1B5C0CE-B7B4-4422-95B1-BD62B3C26211Q34605953-E1427455-D308-4198-84D0-C2ABC07B8705Q35106844-973EBAF2-1402-4EFB-AF63-89CAA0D59EC5Q35146312-934DA54C-66E2-4B00-9173-9B139A224E4AQ35171267-E1B4CFD5-99CB-4E15-AA6A-9368D93F4BB1Q35192790-1EABDAA1-4C17-4409-A48C-6E2FED536B74Q35571035-F929C03B-B966-4DCC-B5D9-776889077C6AQ35602127-E47A7D97-C8E3-4575-A86A-41C9D7FC2C43Q35688742-9FE09E36-C56B-4DEC-9B41-7056F7D6E6DBQ35987564-4BECF7F0-BA1B-43A8-8568-FB54CF9D5348Q36128159-9C369BA8-74B6-43BE-9561-81150E8B9AB9Q36238795-312A6495-2096-4C73-8211-8491D63CEB5CQ36833021-70AC8195-E201-497C-A826-AEAD88E98231Q37025981-94B38C24-CADF-41A8-AB5F-AFAAF45ADFC0Q37027102-CCE9E14A-07EA-44EF-A946-F2FDEFA05719Q37035173-4FE53B28-2987-4663-9306-044CB5A05F2EQ38264774-310F391C-677F-4FBE-BEC7-C79F1CBA073FQ38500371-125AAA2D-3880-457A-9576-DC2A008A2888Q38502885-B976D7E9-25B9-4ECD-A5CC-E4CCA01627B4Q38504437-4A08F40B-F36F-40B0-BD1C-CD67F644A9B1Q38633437-3545D0F7-16EE-4907-B9CE-D3B0493CD90CQ38674733-BC86CE94-95B5-4726-9443-6FD5483ECDEFQ38698520-E9EB4D83-55D6-484A-8D8A-E9AB7733E65BQ38734309-158A10F6-4D55-46CA-94FA-0858BE527544Q38752449-8559E905-A690-4E22-87A1-EF1D458CD9AFQ38843371-2D9E14E4-F9B9-48FD-BF14-FFED494FAEE4Q38922016-1659689B-21E1-4A99-BB37-ABE3BA05A84AQ39014321-99D03762-DA11-48C0-8F5A-DC9193411ABDQ39022777-07565F28-F954-47DB-97E3-E70C969A31C4Q39027852-E3572585-6414-448E-A5C6-E20C973C5E99Q39041475-FE84E13B-A9C5-44E4-B8E1-47AA5CB3479EQ39123286-A132185B-89A6-4A76-AD76-A2D4AF332F9FQ39170500-DBEAEF92-8A95-42B9-8F02-CDEAB7FFF042Q39206217-065098F5-DD4A-4F01-9611-2075C2BAD6FE
P2860
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@ast
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@en
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@nl
type
label
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@ast
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@en
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@nl
prefLabel
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@ast
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@en
Long-term follow-up of imatini ...... Oncology Group study AALL0031.
@nl
P2093
P2860
P50
P356
P1433
P1476
Long-term follow-up of imatini ...... Oncology Group study AALL0031
@en
P2093
Children’s Oncology Group
M J Borowitz
N A Heerema
P2860
P2888
P304
P356
10.1038/LEU.2014.30
P577
2014-01-20T00:00:00Z
P6179
1008558028